A Proof of Concept Study to Evaluate CN-105 in ICH Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

38 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-08-28

Study Completion Date

2020-01-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A multicenter, open-label phase 2a trial of CN-105 in patients with supratentorial intracerebral hemorrhage (ICH). Patients will be evaluated for eligibility within 12 hours of symptom onset. Eligible participants (approximately 60) will receive CN-105 administered intravenously (IV) for a 30-minute infusion every 6 hours for up to a maximum of 3 days (13 doses) or until discharge (if earlier than 3 days). Participants will be monitored daily throughout the Treatment phase of the study (up to a maximum of 5 days) and will receive standard-of-care treatment for the duration of the study. Additional protocol assessments will be required during the Treatment phase. After discharge from the hospital, participants will enter a 3-month Follow-up phase, with a clinic visit at 30 days and a follow-up telephone interview with telephone-validated Modified Rankin Scale (mRS) at 90 days after first dose of study agent.

Funding Source - FDA OOPD

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of CN-105 in Subject With Acute Supratentorial Intracerebral Hemorrhage

NCT03711903

Intracerebral Hemorrhage

COMPLETED PHASE2

Safety Study of CN-105 Neuroprotective Peptide for Intracerebral Hemorrhage

NCT02670824

Intracerebral Hemorrhage (ICH)

COMPLETED PHASE1

Safety and Efficacy Study in Acute Ischaemic Stroke

NCT00144014

Stroke

COMPLETED PHASE2

Statins for Treatment of Primary Intracerebral Hemorrhage

NCT07088250

Cerebrovascular Disorders Intracranial Hemorrhages Intracranial Hemorrhage +1 more

RECRUITING NA

Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke

NCT00075959

Intracerebral Hemorrhage

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intracerebral Hemorrhage

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CN-105

All eligible subjects will receive study drug, CN-105

Group Type EXPERIMENTAL

CN-105

Intervention Type DRUG

Patients with supratentorial intracerebral hemorrhage (ICH) will be evaluated for eligibility within 12 hours of symptom onset. Eligible participants will receive CN-105 administered intravenously (IV) for a 30 -minute infusion every 6 hours for up to a maximum of 3 days (13 doses) or until discharge (if earlier than 3 days)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CN-105

Patients with supratentorial intracerebral hemorrhage (ICH) will be evaluated for eligibility within 12 hours of symptom onset. Eligible participants will receive CN-105 administered intravenously (IV) for a 30 -minute infusion every 6 hours for up to a maximum of 3 days (13 doses) or until discharge (if earlier than 3 days)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Has given written informed consent to participate in the study in accordance with required regulations; if a participant is not capable of providing informed consent, written consent must be obtained from the participant's legally authorized representative (LAR).
2. Stated willingness to comply with all study procedures and availability for the duration of the study.
3. Is male or female, age 30 to 80 years, inclusive.
4. Has a confirmed diagnosis of spontaneous supratentorial ICH.
5. Able to receive first dose of study drug ≤ 12 hours after onset of ICH symptoms, such as alteration in level of consciousness, severe headache, nausea, vomiting, seizure, and/or focal neurological deficits, or last-known well time.
6. Has an interpretable and measurable diagnostic CT scan.
7. Has a Glasgow Coma Scale (GCS) score ≥ 5 on presentation
8. Has a National Institutes of Health Stroke Scale (NIHSS) score ≥ 4.
9. Has systolic BP (SBP) \< 200 mm Hg at enrollment.

Exclusion Criteria

1. Is pregnant or lactating.
2. Has a temperature greater than 38.5°C at Screening.
3. Has ICH resulting from trauma.
4. Has infratentorial hemorrhage (any involvement of the midbrain or lower brainstem as demonstrated by radiograph or complete third nerve palsy).
5. Has primary intraventricular hemorrhage deemed to be at high risk for obstructive hydrocephalus, or extra-axial (ie, subarachnoid or subdural) extension of hemorrhage.
6. Has radiographic evidence of underlying tumor.
7. Has an unstable mass or evolving intracerebral compartment syndrome.
8. Has a ruptured aneurysm, arteriovenous malformation, or vascular anomaly.
9. Has a platelet count \< 100,000/mL.
10. Has an international normalized ratio (INR) \< 1.6 or irreversible coagulopathy either due to medical condition or detected before screening.
11. In the opinion of the investigator is unstable and would benefit from supportive care rather than supportive care plus CN-105.
12. In the opinion of the investigator has any contraindication to the planned study assessments, including CT and MRI.
13. Any condition which could interfere with, or the treatment for which might interfere with, the conduct of the study or which, in the opinion of the investigator, unacceptably increases the individual's risk by participating in the study.
14. Concomitant enrollment in another interventional study.

Minimum Eligible Age

30 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No